

Attorney Docket No.: 3985.240-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Havelund et al.

Serial No.: 09/398,365

Group Art Unit: 1656

Filed: September 17, 1999

Examiner: Siew, J.

Confirmation No.: 9987

For: Acylated Insulin

**TERMINAL DISCLAIMER UNDER 37 CFR 1.321**

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application as evidenced by the assignment from the named inventors to Novo Nordisk A/S in parent application 08/975,365 that was as recorded on January 20, 1998 at Reel 8906, Frame 0893.

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,011,007, issued January 4, 2000, is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,011,007. In part January 4, 2000, this agreement to disclaim with any patent granted on the


patent granted on the above-identified application that would extend beyond the expiration date of

the full statutory term of U.S. Patent No. 6,011,007, issued January 4, 2000, in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The Commissioner of Patents is hereby authorized to charge the fee required under 37 C.F.R. 1.20(d) for the filing of this Terminal Disclaimer, estimated to be \$110.00, to Deposit Account No.14-1447. A duplicate of this sheet is enclosed

Respectfully submitted,

Date: October 8, 2003

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

23650

PATENT/TRADEMARK OFFICE

RECEIVED  
400 1st ST. SEATTLE